Laboratorio Farmaceutico Erfo SpAMIL:ERFO -2.54%68 EBITDA Margin % is 16.82% as of Dec. 2025, which is 51% below its 10-year median of 34.08. GuruFocus rates MIL:ERFO with a GF Score™ of 68/100 and a GF Value™ of €2.10 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,949 Consumer Packaged Goods companies, Laboratorio Farmaceutico Erfo SpA ranks better than 84.71% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Laboratorio Farmaceutico Erfo SpA EBITDA Margin % Related Terms
Laboratorio Farmaceutico Erfo SpA EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:ERFO vs KHC, GIS, HRL: EBITDA Margin % Comparison
For the Packaged Foods subindustry, Laboratorio Farmaceutico Erfo SpA's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorio Farmaceutico Erfo SpA EBITDA Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Laboratorio Farmaceutico Erfo SpA's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Laboratorio Farmaceutico Erfo SpA's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) has a EBITDA Margin % of 16.82% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Laboratorio Farmaceutico Erfo SpA and its competitors. This is 51% below median its historical median of 34.08. Over the past decade, Laboratorio Farmaceutico Erfo SpA's EBITDA Margin % has ranged from 20.59 to 43.92. According to the industry distribution chart, Laboratorio Farmaceutico Erfo SpA ranks #298 out of 1949 companies in the Consumer Packaged Goods industry, placing it in the top 15.3%.
Is Laboratorio Farmaceutico Erfo SpA's EBITDA Margin % too high?
Laboratorio Farmaceutico Erfo SpA's current EBITDA Margin % of 16.82% is 51% below median its 10-year median of 34.08. Over the past 10 years, this metric has ranged from a low of 20.59 to a high of 43.92. The Consumer Packaged Goods industry median EBITDA Margin % is 8.97. Laboratorio Farmaceutico Erfo SpA's value of 16.82% is 87.5% above this industry median. Based on the distribution chart, Laboratorio Farmaceutico Erfo SpA ranks #298 out of 1949 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Laboratorio Farmaceutico Erfo SpA has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorio Farmaceutico Erfo SpA's EBITDA Margin % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Laboratorio Farmaceutico Erfo SpA ranks #298 out of 1949 companies for EBITDA Margin %. This places Laboratorio Farmaceutico Erfo SpA in the top 15% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 8.97. Laboratorio Farmaceutico Erfo SpA's value of 16.82% is 87.5% above this benchmark. Historically, Laboratorio Farmaceutico Erfo SpA's own EBITDA Margin % has ranged from 20.59 to 43.92 over the past decade. While the company's 10-year median is 34.08 vs. the industry median of 8.97, Laboratorio Farmaceutico Erfo SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 8.97, based on 1,949 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorio Farmaceutico Erfo SpA's current EBITDA Margin % of 16.82% is 87.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Laboratorio Farmaceutico Erfo SpA and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 8.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorio Farmaceutico Erfo SpA's current EBITDA Margin % is 16.82%, which is 51% below median its own 10-year median of 34.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorio Farmaceutico Erfo SpA stock overvalued right now?
Based on GuruFocus' analysis, Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.10, compared to a current price of €1.15 — trading 45.2% below its estimated fair value. The current EBITDA Margin % is 16.82%, which is 51% below median its 10-year median of 34.08 and 87.5% above the Consumer Packaged Goods industry median of 8.97. Laboratorio Farmaceutico Erfo SpA's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Laboratorio Farmaceutico Erfo SpA (MIL:ERFO), the current EBITDA Margin % is 16.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorio Farmaceutico Erfo SpA stock appears to be undervalued.
The current stock price of €1.15 is trading 45.2% below its estimated GF Value™ of €2.10.
GuruFocus considers Laboratorio Farmaceutico Erfo SpA to be Significantly Undervalued.
Key valuation signals for MIL:ERFO:
EBITDA Margin %: 16.82% (51% below median its 10-year median of 34.08)
GF Value™: €2.10 vs. price of €1.15 (45.2% below fair value)
Industry Position: 87.5% above the Consumer Packaged Goods median (#298 of 1949)
No single metric tells the full story. See the MIL:ERFO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorio Farmaceutico Erfo SpA Business Description
Laboratorio Farmaceutico Erfo SpA operates in the nutraceutical sector. The company specializes in formulating and producing food supplements and natural medicines in different forms such as liquids, powders, granules, tablets, and soft gels. Geographically, the company generates a majority of its revenue from Italy followed by Spain, France, Belgium, and other countries.
68GF Score
Get the complete analysis for MIL:ERFO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:ERFO has been successfully added to your 
